$NPHC The company previously announced that they had been granted an Orphan Designation from the US-FDA (Food and Drug Administration) for the treatment of Pediatric Multiple Sclerosis with RPI-78M. The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.